SciSparc Unveils Groundbreaking Patent Publication
In a significant development, SciSparc Ltd. (Nasdaq: SPRC), a pioneering clinical-stage pharmaceutical firm, has announced the publication of a Japanese divisional patent, which holds immense promise for advancing pain management therapies. The company is dedicated to creating effective treatments aimed at addressing disorders affecting the central nervous system.
This newly published patent introduces an innovative pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA). This combination is poised to deliver superior pain and fever relief while potentially reducing dosages and side effects that often accompany traditional paracetamol usage. As a result, it offers an exciting opportunity for safer and more effective treatment options for countless individuals across the globe.
Innovative Therapy for Enhanced Patient Care
Oz Adler, the Chief Executive Officer of SciSparc, remarked on the significance of this patent, highlighting its transformational potential in pain management. He explained that the combination of paracetamol, a common analgesic, with PEA, a natural compound that enhances the body’s endocannabinoid system, could represent a major step forward in treatment capabilities.
The synergistic effect of paracetamol and PEA may enable healthcare providers to use lower doses of paracetamol, thereby minimizing the risk of liver damage and other potential adverse effects. Such advancements not only aim to improve pain management in patients suffering from acute, chronic, and neuropathic pain but also address challenges associated with fever management.
About SciSparc Ltd.
SciSparc Ltd. operates at the forefront of pharmaceutical innovation, driven by a dynamic team of experienced professionals committed to developing cannabinoid-based therapies. The company is focused on expanding its portfolio of technologies and drug development programs that leverage both THC and non-psychoactive cannabidiol.
Among its key initiatives, SciSparc is working on SCI-110, dedicated to treating Tourette Syndrome, and other conditions such as Alzheimer's disease and agitation. Furthermore, SCI-210 is under development for autism treatment and status epilepticus. In addition to these pharmaceutical efforts, the company maintains a controlling stake in a subsidiary that specializes in selling hemp seed oil-based products through online platforms.
Strategic Vision for Future Developments
SciSparc's focus on cannabinoid pharmaceuticals is more than just about creating new medications; it embodies a vision for a safer healthcare approach that could benefit millions around the world. As the company continues its innovative journey, its commitment to improving patient outcomes remains paramount.
With ongoing research and development into cannabinoid therapies, the potential for groundbreaking treatments could reshape the landscape of pain management and offer hope for numerous patients seeking relief from chronic conditions.
Investor Relations
For those interested in learning more about SciSparc's activities or discussing potential investment opportunities, they encourage reaching out through the following contact information:
Email: IR@scisparc.com
Phone: +972-3-6167055
Frequently Asked Questions
What is the focus of SciSparc Ltd.?
SciSparc Ltd. focuses on developing innovative therapies to treat disorders impacting the central nervous system.
What is the significance of the recently published patent?
This patent introduces a combination of paracetamol and PEA that aims to enhance pain and fever relief with fewer side effects.
How does the drug combination benefit patients?
The combination may allow for lower doses of paracetamol, thus reducing the risks associated with higher dosages while improving treatment outcomes.
What conditions are SciSparc's treatments targeting?
SciSparc's programs are directed at Tourette Syndrome, Alzheimer's disease, autism, and other central nervous system disorders.
How can investors get in touch with SciSparc?
Investors can contact the company via email at IR@scisparc.com or call at +972-3-6167055.
